Published in Clin Lipidol on August 01, 2011
Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. AIDS Res Ther (2013) 1.04
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses (2012) 0.88
HIV stroke risk: evidence and implications. Ther Adv Chronic Dis (2013) 0.86
Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study. HIV AIDS (Auckl) (2016) 0.75
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. HIV AIDS (Auckl) (2017) 0.75
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med (1999) 16.30
Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 14.01
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation (2007) 11.95
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 9.97
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation (2006) 6.17
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA (1984) 5.65
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr (2007) 4.67
Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab (1992) 4.25
Impact of HIV infection and HAART on serum lipids in men. JAMA (2003) 4.01
Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol (2006) 3.48
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS (2010) 3.27
Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol (2000) 3.17
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS (2009) 3.08
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS (2008) 2.72
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis (2007) 2.69
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (2002) 2.59
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis (2003) 2.54
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis (2004) 2.26
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med (2003) 1.98
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS (2009) 1.93
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis (2005) 1.76
Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol (2003) 1.76
Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS (2009) 1.67
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr (2005) 1.67
HIV infection and high density lipoprotein metabolism. Atherosclerosis (2007) 1.62
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr (2008) 1.57
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol (2010) 1.50
HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart (2009) 1.42
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis (2007) 1.39
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses (2005) 1.37
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis (2011) 1.32
The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med (2005) 1.30
Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med (2007) 1.26
Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr (2008) 1.24
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS (2006) 1.24
Dyslipidemia and its Treatment in HIV Infection. Top HIV Med (2010) 1.24
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr (2007) 1.20
Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One (2008) 1.20
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr (2008) 1.15
Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol (2008) 1.14
Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (2008) 1.14
The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials (2007) 1.12
Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med (2009) 1.12
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS (2005) 1.07
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS (2010) 1.05
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther (2006) 1.05
Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials (2009) 1.04
Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis (2004) 1.02
A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS (2002) 1.01
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res (2008) 1.00
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr (2009) 0.99
Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circ Cardiovasc Genet (2009) 0.99
Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med (2009) 0.99
Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection (2002) 0.99
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis (2007) 0.97
Switching strategies to improve lipid profile and morphologic changes. AIDS Rev (2007) 0.97
Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis (2008) 0.97
Platelet function and HIV: a case-control study. AIDS (2010) 0.97
Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr (2007) 0.95
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS (2010) 0.93
European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS (2011) 0.93
Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS (2001) 0.90
Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS (2006) 0.90
Insulin resistance in HIV-infected men and women in the nutrition for healthy living cohort. J Acquir Immune Defic Syndr (2005) 0.88
Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol (2009) 0.88
Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. J Intern Med (2010) 0.87
Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis (2004) 0.87
Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am (2009) 0.86
The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther (2010) 0.86
Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics. Pharmacogenomics (2010) 0.85
Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis (2001) 0.85
Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy (2000) 0.83
Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV. Curr Opin HIV AIDS (2008) 0.83
Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDS (2000) 0.83
Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia. HIV Clin Trials (2007) 0.82
Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients. AIDS Res Hum Retroviruses (2008) 0.82
Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 0.81
Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS (2009) 0.80
Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. J Acquir Immune Defic Syndr (2010) 0.79
Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults. AIDS (2010) 0.79
Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor. Nutrition (2001) 0.79
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Development of national and multiagency HIV care quality measures. Clin Infect Dis (2010) 2.79
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (2002) 2.59
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis (2004) 2.17
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 2.02
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother (2002) 1.75
Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS (2008) 1.71
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr (2005) 1.67
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
Coronary heart disease in people infected with HIV. Cleve Clin J Med (2010) 1.52
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol (2010) 1.50
Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. Sex Transm Infect (2011) 1.43
Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis (2005) 1.43
Health needs of HIV-infected women in the United States: insights from the women living positive survey. AIDS Patient Care STDS (2011) 1.30
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr (2008) 1.15
Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr (2013) 1.11
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS (2010) 1.05
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther (2006) 1.05
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis (2002) 1.03
Care for transgender persons. JAMA (2013) 0.97
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis (2009) 0.96
Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities. PLoS Med (2011) 0.96
Neuropsychiatric complications of antiretroviral therapy. Drug Saf (2006) 0.94
The changing face of HIV care: common things really are common. Ann Intern Med (2006) 0.94
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther (2005) 0.93
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis (2004) 0.90
Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. AIDS Patient Care STDS (2012) 0.89
Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS (2010) 0.86
Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort. J Acquir Immune Defic Syndr (2014) 0.85
Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087. HIV Clin Trials (2007) 0.85
Pulmonary cryptococcosis in normal hosts: treat or observe? Chest (2003) 0.83
Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. J Acquir Immune Defic Syndr (2013) 0.83
Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women. J Acquir Immune Defic Syndr (2003) 0.83
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin Pharmacol Ther (2003) 0.82
Cardiac risk: not so simple. J Infect Dis (2010) 0.82
Cardiovascular and Endothelial Disease in HIV Infection. Curr Infect Dis Rep (2005) 0.82
Dyslipidemia in HIV patients. Cleve Clin J Med (2005) 0.82
Discontinuation of antiretroviral therapy postpartum: no evidence for altered viral set point. J Acquir Immune Defic Syndr (2007) 0.81
Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterol (2011) 0.81
Letter in response to the new SHEA guideline for healthcare workers with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol (2010) 0.80
Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr (2014) 0.80
Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. AIDS Res Hum Retroviruses (2012) 0.79
Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals. Expert Rev Anti Infect Ther (2007) 0.79
Cure of acute hepatitis C in HIV co-infection? J Clin Gastroenterol (2004) 0.78
GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. Open Virol J (2011) 0.78
Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. Clin Infect Dis (2010) 0.77
High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. AIDS (2011) 0.77
Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS (2017) 0.76
Clash of the microbes: let's bring back the good guys. J Clin Invest (2013) 0.75
Case files from the Bellevue Hospital Center at New York University--lipoatrophy following long-term antiretroviral therapy. MedGenMed (2005) 0.75
A tale of two fungi in a person with HIV. MedGenMed (2006) 0.75
HIV counseling and testing for household members of HIV-infected individuals in Africa: should prevention programs focus on home-based rather than clinic-based outreach? Curr HIV/AIDS Rep (2011) 0.75
Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City. Int J Infect Dis (2012) 0.75
Assessing Antiretroviral Use During Gaps in HIV Primary Care Using Multisite Medicaid Claims and Clinical Data. J Acquir Immune Defic Syndr (2017) 0.75
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis (2006) 0.75
Gonorrhea and Chlamydia Case Detection Increased When Testing Increased in a Multisite US HIV Cohort, 2004-2014. J Acquir Immune Defic Syndr (2017) 0.75
Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV Clin Trials (2003) 0.75
Oral shedding of Herpesviruses in HIV+ patients with varying degrees of immune status. AIDS (2017) 0.75